N6F11 is a ferroptosis inducer, and can trigger the degradation of glutathione peroxidase 4 (GPX4) specifically in cancer cells. N6F11 can be used for ferroptosis study.

BPKDi is a potent bipyridyl PKD inhibitor with IC50s of 1 nM, 9 nM and 1 nM for PKD1, PKD2 and PKD3, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes.

BAY 1892005 is a small molecule that modulate mutant p53 condensation and nuclear accumulation, binds covalently to mutant p53R175H and p53Y220C and shows stabilization of p53WT and p53Y220C, exhibits anti-proliferative activity in a set of cell lines wit

SRS11-92, a Ferrostatin-1 (Fer-1) analogue, is a potent ferroptosis inhibitor. SRS11-92 inhibits ferroptotic cell death induced by Erastin in HT-1080 human fibrosarcoma cells (EC50=6 nM).

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.

A-1155463 is a highly potent and selective BCL-XL inhibitor.

Nutlin-3a is arbitrarily referred to as enantiomer a because it appears as the first peak from chiral purification of racemic nutlin-3 and its absolute stereocenter assignment is not known.

Nutlin 3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.

PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 suppresses glioma progression in vitro and in vivo. PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis. PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability.

Lacutoclax is a Bcl-2 inhibitor with antineoplastic activity.

BTM-3566 is an OMA1 activator. BTM-3566 activates the mitochondrial stress response. BTM-3566 induces apoptosis in diffuse large B-cell lymphomas (DLBCL) cell lines.

Zharp2-1 is a novel potent, selective RIPK2 inhibitor with IC50 of 38.5 nM in ADP-Glo kinase assay, effectively blocks RIPK2 kinase function and NOD-mediated NF-κB/MAPK activation.

Zharp1-211 is a potent, selective, type II inhibitor of RIPK1 kinase with IC50 of 53 nM and binding Kd of 8.7 nM.

Oditrasertib is a potent, selective RIPK1 inhibitor.

GSK2593074A (GSK'074, GSK-2593074A) is novel potent, selective RIP1/RIP3 kinase dual inhibitor, directly binds to RIP1 and RIP3 with Kd of 130 and 12 nM, respectively.

Flizasertib is a potent, selective RIP1 kinase (RIPK1) inhibitor with potential for treating prophylaxis.

cRIPGBM (RIPGBM derivative cRIPGBM, RIPGBM-18) is a metabolite of RIPGBM induces apoptosis in GBM CSCs (EC50=68 nM in GBM 1 cells) by interacting with RIPK2 (Kd=2.3 uM).

aYM155 is a brain-penetrating prodrug form of YM155 (Cat. PC-42439, potent survivin inhibitor), displays potent cell killing activity against a broad panel of patient-derived GBM cancer stem-like cells (IC50=0.7-10 nM).

UCI-LC0023 is a small molecule that restores mutant p53 activity by targeting the cryptic L1/S3 pocket of p53, directly binds to mutant p53 and restores wild-type-like conformation of mutant p53R175H.

UCI-LC0019 is a specific small molecule that restores mutant p53 activity by targeting the cryptic L1/S3 pocket of p53, directly binds to mutant p53 and restores wild-type-like conformation of mutant p53R175H.

UC2288 is a small molecule p21 inhibitor, attenuates p21 protein abundance at 10 µM, independently of p53 activity and at the level of transcription or post-transcription.

ReACp53 is a cell-penetrating 17-residue peptide designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines.

NSC146109 (XI-011) is a small-molecule p53 activator, induces apoptosis of breast cancer cells through inhibiting MDMX (MDM4) expression.

Morncide (Morn3 (222-237)) is a cell-penetrating, 16-AA Morn3-targeting peptide that disrupts the interaction between p53 and Morn3-mediated complex, Morncide peptide stabilizes and reactivates p53 in cancer cells.

MMRi71 is a small molecule inhibitor of the E3 ligase activity of MDM2-MDM4, and an inducer of MDM4 and FTH1 dual protein degradation and p53-independent apoptosis in leukemia cells.

MMRi67 is a potent E3 ligase inhibitor of the MDM2-MDM4 E3 complex, inhibits RING-RING interaction of MDM4 and MDM2B with Kd of 896 nM.

K-181 is a specific small-molecule Protein-Protein Interaction (PPI) inhibitor of Mdmx-p53 interaction, exhibits neuroprotective effects on ischemic stroke by disrupting Mdmx-p53 interaction and inhibiting HDAC6 activity.

GY1-22 is a small molecule inhibitor against DNAJA1-mutP53R175H interacting pocket, reduces mutp53 protein expression in colon cancer cell line with p53R175H mutation.

BAY 249716 is a small molecule that modulate mutant p53 condensation, showed significant stabilization of all three p53 protein variants, p53WT p53R175H and p53Y220C.

RMT 5265 (RMT5265) is a potent, small molecule bivalent mimic of Smac, inhibits XIAP and cIAP1/2 through the BIR3 domain.